S&P 500   3,254.44 (-1.25%)
DOW   28,630.39 (-1.24%)
QQQ   218.94 (-1.69%)
AAPL   310.50 (-2.45%)
FB   215.24 (-1.24%)
MSFT   162.88 (-1.31%)
GOOGL   1,432.60 (-2.29%)
AMZN   1,833.82 (-1.49%)
CGC   21.87 (-3.44%)
NVDA   241.07 (-3.76%)
BABA   206.81 (-3.25%)
MU   55.72 (-3.53%)
GE   11.50 (-1.79%)
TSLA   560.43 (-0.78%)
AMD   49.44 (-1.81%)
T   38.48 (-0.05%)
ACB   1.90 (-4.52%)
F   8.90 (-1.11%)
NFLX   343.69 (-2.68%)
PRI   119.75 (-2.27%)
BAC   32.93 (-1.85%)
DIS   136.47 (-2.58%)
GILD   64.00 (+1.35%)
S&P 500   3,254.44 (-1.25%)
DOW   28,630.39 (-1.24%)
QQQ   218.94 (-1.69%)
AAPL   310.50 (-2.45%)
FB   215.24 (-1.24%)
MSFT   162.88 (-1.31%)
GOOGL   1,432.60 (-2.29%)
AMZN   1,833.82 (-1.49%)
CGC   21.87 (-3.44%)
NVDA   241.07 (-3.76%)
BABA   206.81 (-3.25%)
MU   55.72 (-3.53%)
GE   11.50 (-1.79%)
TSLA   560.43 (-0.78%)
AMD   49.44 (-1.81%)
T   38.48 (-0.05%)
ACB   1.90 (-4.52%)
F   8.90 (-1.11%)
NFLX   343.69 (-2.68%)
PRI   119.75 (-2.27%)
BAC   32.93 (-1.85%)
DIS   136.47 (-2.58%)
GILD   64.00 (+1.35%)
S&P 500   3,254.44 (-1.25%)
DOW   28,630.39 (-1.24%)
QQQ   218.94 (-1.69%)
AAPL   310.50 (-2.45%)
FB   215.24 (-1.24%)
MSFT   162.88 (-1.31%)
GOOGL   1,432.60 (-2.29%)
AMZN   1,833.82 (-1.49%)
CGC   21.87 (-3.44%)
NVDA   241.07 (-3.76%)
BABA   206.81 (-3.25%)
MU   55.72 (-3.53%)
GE   11.50 (-1.79%)
TSLA   560.43 (-0.78%)
AMD   49.44 (-1.81%)
T   38.48 (-0.05%)
ACB   1.90 (-4.52%)
F   8.90 (-1.11%)
NFLX   343.69 (-2.68%)
PRI   119.75 (-2.27%)
BAC   32.93 (-1.85%)
DIS   136.47 (-2.58%)
GILD   64.00 (+1.35%)
S&P 500   3,254.44 (-1.25%)
DOW   28,630.39 (-1.24%)
QQQ   218.94 (-1.69%)
AAPL   310.50 (-2.45%)
FB   215.24 (-1.24%)
MSFT   162.88 (-1.31%)
GOOGL   1,432.60 (-2.29%)
AMZN   1,833.82 (-1.49%)
CGC   21.87 (-3.44%)
NVDA   241.07 (-3.76%)
BABA   206.81 (-3.25%)
MU   55.72 (-3.53%)
GE   11.50 (-1.79%)
TSLA   560.43 (-0.78%)
AMD   49.44 (-1.81%)
T   38.48 (-0.05%)
ACB   1.90 (-4.52%)
F   8.90 (-1.11%)
NFLX   343.69 (-2.68%)
PRI   119.75 (-2.27%)
BAC   32.93 (-1.85%)
DIS   136.47 (-2.58%)
GILD   64.00 (+1.35%)
Log in

NASDAQ:FGEN - FibroGen Stock Price, Forecast & News

$42.03
+0.23 (+0.55 %)
(As of 01/27/2020 02:13 PM ET)
Today's Range
$40.40
Now: $42.03
$42.11
50-Day Range
$41.78
MA: $44.73
$48.01
52-Week Range
$32.33
Now: $42.03
$61.23
Volume271,829 shs
Average Volume584,247 shs
Market Capitalization$3.67 billion
P/E Ratio107.77
Dividend YieldN/A
Beta1.86
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$212.96 million
Book Value$6.22 per share

Profitability

Net Income$-86,420,000.00

Miscellaneous

Employees461
Market Cap$3.67 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.


FibroGen (NASDAQ:FGEN) Frequently Asked Questions

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen Inc (NASDAQ:FGEN) issued its quarterly earnings results on Monday, November, 11th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.02. The biopharmaceutical company earned $33.17 million during the quarter, compared to analysts' expectations of $31.61 million. FibroGen had a return on equity of 7.33% and a net margin of 11.81%. The business's quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. View FibroGen's Earnings History.

When is FibroGen's next earnings date?

FibroGen is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for FibroGen.

What price target have analysts set for FGEN?

5 analysts have issued 1-year price objectives for FibroGen's shares. Their forecasts range from $40.00 to $72.00. On average, they expect FibroGen's share price to reach $57.00 in the next year. This suggests a possible upside of 35.6% from the stock's current price. View Analyst Price Targets for FibroGen.

What is the consensus analysts' recommendation for FibroGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.

Has FibroGen been receiving favorable news coverage?

News articles about FGEN stock have been trending somewhat negative this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. FibroGen earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for FibroGen.

Who are some of FibroGen's key competitors?

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), ALJ Regional (ALJJ) and Transocean (RIG).

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:
  • Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)
  • Mr. Pat Cotroneo, Sr. VP of Fin. & CFO (Age 55)
  • Dr. K. Peony Yu, Chief Medical Officer (Age 57)
  • Mr. Julian N. Stern, Sec. (Age 94)
  • Dr. Barry A. Berkowitz, Founder

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.32%), Assenagon Asset Management S.A. (0.08%), Woodstock Corp (0.03%), Virginia Retirement Systems ET AL (0.02%), Strs Ohio (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Which institutional investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Rhenman & Partners Asset Management AB and Nisa Investment Advisors LLC. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, Elias Kouchakji, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo and Thomas B Neff. View Insider Buying and Selling for FibroGen.

Which institutional investors are buying FibroGen stock?

FGEN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Virginia Retirement Systems ET AL, Woodstock Corp and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for FibroGen.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $42.03.

How big of a company is FibroGen?

FibroGen has a market capitalization of $3.67 billion and generates $212.96 million in revenue each year. The biopharmaceutical company earns $-86,420,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. FibroGen employs 461 workers across the globe.View Additional Information About FibroGen.

What is FibroGen's official website?

The official website for FibroGen is http://www.fibrogen.com/.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]


MarketBeat Community Rating for FibroGen (NASDAQ FGEN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  302 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  593
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: What is Green Investing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel